The state of Florida is apparently ready to secede from the US Food & Drug Administration.
Florida Versus US FDA ... Again
The very public attempt by the state of Florida to question FDA’s decision on COVID monoclonal antibodies is the latest example of how the politics of COVID is roiling the agency’s reputation. But is it really so different than Florida’s pre-pandemic plans to import drugs from Canada?
More from Pricing Debate
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.
More from Market Access
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.